Standout Papers

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderat... 2021 2026 2022 2024199
  1. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Sarah Diver, Latifa Khalfaoui et al. The Lancet Respiratory Medicine
  2. Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps (2025)
    Joseph K. Han, Martin Desrosiers et al. New England Journal of Medicine

Immediate Impact

14 standout
Sub-graph 1 of 6

Citing Papers

ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
2025 Standout
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma
2024 Standout
1 intermediate paper

Works of Ayman Megally being referenced

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Ayman Megally 320 147 158 11 367
M. Zheng 201 218 36 9 383
Guillaume Mahay 254 75 72 10 383
L.C. Lau 283 117 200 15 406
Justus Adédoyin 229 299 91 9 368
O.J. Corrado 191 205 90 11 378
Benny Dua 226 105 71 12 313
S.M. Reinartz 197 183 69 18 334
Junichi Ohtawa 317 124 260 15 358
Zev M. Munk 331 179 239 14 403
E Martí-Guadaño 293 273 104 9 366

All Works

Loading papers...

Rankless by CCL
2026